A double-blind, randomized, controlled trial on the effect of PEX010 for prolonged grief disorder

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518218-24-00

Enrollment

120

Registered

2025-02-10

Start date

2025-07-17

Completion date

Unknown

Last updated

2025-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prolonged grief disorder

Brief summary

Score on PG13-R

Detailed description

Score on PG13-R

Interventions

DRUGPEX010 Psilocybin Capsules (1mg psilocybin)

DRUGPEX010 Psilocybin Capsules (25 mg psilocybin)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Score on PG13-R	—

Secondary

Measure	Time frame
Score on PG13-R	—

Countries

Sweden

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026